Koji Iinuma

26PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPodiatry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 15, 2026
Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med. 2021, 10, 5325.

|Jun 12, 2026
Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

|May 20, 2026
Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

|Mar 29, 2026
Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.

Kojiro Niwa, Koji Iinuma, Masahiro Nakano

|Dec 11, 2025
Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review.

Koji Iinuma, Masayuki Tomioka, Tomoki Taniguchi

|Oct 01, 2025
Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly-Metastatic Prostate Cancer.

Makoto Kawase, Kota Kawase, Yuki Tobisawa

Pageof 5

Frequent Collaborators

22 joint publications

Takuya Koie

12 joint publications

Keita Nakane

12 joint publications

Makoto Kawase

10 joint publications

Daiki Kato